{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:53:44Z","timestamp":1791381224101,"version":"4.3.3"},"reference-count":38,"publisher":"American Diabetes Association","issue":"6","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":3021,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,6,1]]},"abstract":"<jats:p>Our objective was to determine if the insulin-sensitizing drug pioglitazone acutely reduces insulin secretion and causes metabolic deceleration in vivo independently of change in insulin sensitivity. We assessed glucose homeostasis by hyperinsulinemic-euglycemic and hyperglycemic clamp studies and energy expenditure by indirect calorimetry and biotelemetry in male Wistar and obese hyperinsulinemic Zucker diabetic fatty (ZDF) rats 45 min after a single oral dose of pioglitazone (30 mg\/kg). In vivo insulin secretion during clamped hyperglycemia was reduced in both Wistar and ZDF rats after pioglitazone administration. Insulin clearance was slightly increased in Wistar but not in ZDF rats. Insulin sensitivity in Wistar rats assessed by the hyperinsulinemic-euglycemic clamp was minimally affected by pioglitazone at this early time point. Pioglitazone also reduced energy expenditure in Wistar rats without altering respiratory exchange ratio or core body temperature. Glucose-induced insulin secretion (GIIS) and oxygen consumption were reduced by pioglitazone in isolated islets and INS832\/13 cells. In conclusion, pioglitazone acutely induces whole-body metabolic slowing down and reduces GIIS, the latter being largely independent of the insulin-sensitizing action of the drug. The results suggest that pioglitazone has direct metabolic deceleration effects on the \u03b2-cell that may contribute to its capacity to lower insulinemia and antidiabetic action.<\/jats:p>","DOI":"10.2337\/db12-0428","type":"journal-article","created":{"date-parts":[[2013,2,2]],"date-time":"2013-02-02T05:33:08Z","timestamp":1359783188000},"page":"2122-2129","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":38,"title":["Pioglitazone Acutely Reduces Energy Metabolism and Insulin Secretion in Rats"],"prefix":"10.2337","volume":"62","author":[{"given":"Julien","family":"Lamontagne","sequence":"first","affiliation":[{"name":"Molecular Nutrition Unit and Montreal Diabetes Research Center at the Centre de Recherche du Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CRCHUM), Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"},{"name":"Department of Biochemistry, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9lise","family":"Jalbert-Arsenault","sequence":"additional","affiliation":[{"name":"Molecular Nutrition Unit and Montreal Diabetes Research Center at the Centre de Recherche du Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CRCHUM), Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"},{"name":"Department of Nutrition, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9milie","family":"Pepin","sequence":"additional","affiliation":[{"name":"Molecular Nutrition Unit and Montreal Diabetes Research Center at the Centre de Recherche du Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CRCHUM), Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"},{"name":"Program of Molecular Biology, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Line","family":"Peyot","sequence":"additional","affiliation":[{"name":"Molecular Nutrition Unit and Montreal Diabetes Research Center at the Centre de Recherche du Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CRCHUM), Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil B.","family":"Ruderman","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Physiology and Biophysics, Boston University School of Medicine and Diabetes Unit, Section of Endocrinology, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Nolan","sequence":"additional","affiliation":[{"name":"The Australian National University Medical School, Canberra, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Joly","sequence":"additional","affiliation":[{"name":"Molecular Nutrition Unit and Montreal Diabetes Research Center at the Centre de Recherche du Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CRCHUM), Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.R. Murthy","family":"Madiraju","sequence":"additional","affiliation":[{"name":"Molecular Nutrition Unit and Montreal Diabetes Research Center at the Centre de Recherche du Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CRCHUM), Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Poitout","sequence":"additional","affiliation":[{"name":"Montreal Diabetes Research Center at the CRCHUM and Departments of Medicine, Biochemistry and Nutrition, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Prentki","sequence":"additional","affiliation":[{"name":"Molecular Nutrition Unit and Montreal Diabetes Research Center at the Centre de Recherche du Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CRCHUM), Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"},{"name":"Department of Nutrition, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"},{"name":"Department of Biochemistry, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2013,5,20]]},"reference":[{"key":"2022031210275318600_B1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/db11-1483","article-title":"Banting lecture 2011: hyperinsulinemia: cause or consequence?","volume":"61","author":"Corkey","year":"2012","journal-title":"Diabetes"},{"key":"2022031210275318600_B2","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1172\/JCI29103","article-title":"Islet beta cell failure in type 2 diabetes","volume":"116","author":"Prentki","year":"2006","journal-title":"J Clin Invest"},{"key":"2022031210275318600_B3","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.2337\/dc08-s264","article-title":"Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse?","volume":"31","author":"Shanik","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031210275318600_B4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0140-6736(11)60614-4","article-title":"Type 2 diabetes across generations: from pathophysiology to prevention and management","volume":"378","author":"Nolan","year":"2011","journal-title":"Lancet"},{"key":"2022031210275318600_B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.metabol.2010.09.010","article-title":"Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes","volume":"60","author":"Nyenwe","year":"2011","journal-title":"Metabolism"},{"key":"2022031210275318600_B6","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1007\/s00125-004-1436-1","article-title":"Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin","volume":"47","author":"Ye","year":"2004","journal-title":"Diabetologia"},{"key":"2022031210275318600_B7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1172\/JCI28003","article-title":"PPAR gamma and human metabolic disease","volume":"116","author":"Semple","year":"2006","journal-title":"J Clin Invest"},{"key":"2022031210275318600_B8","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1463-1326.2010.01299.x","article-title":"The role of peroxisome proliferator-activated receptor \u03b3 in pancreatic \u03b2 cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus","volume":"12","author":"Gupta","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"2022031210275318600_B9","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1210\/en.2008-1557","article-title":"Pioglitazone acutely reduces insulin secretion and causes metabolic deceleration of the pancreatic beta-cell at submaximal glucose concentrations","volume":"150","author":"Lamontagne","year":"2009","journal-title":"Endocrinology"},{"key":"2022031210275318600_B10","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.2337\/diabetes.53.4.1052","article-title":"Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?","volume":"53","author":"Brunmair","year":"2004","journal-title":"Diabetes"},{"key":"2022031210275318600_B11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.mce.2009.09.031","article-title":"Obesity and type 2 diabetes: slow down!\u2014Can metabolic deceleration protect the islet beta cell from excess nutrient-induced damage?","volume":"316","author":"Andrikopoulos","year":"2010","journal-title":"Mol Cell Endocrinol"},{"key":"2022031210275318600_B12","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s00125-008-0930-2","article-title":"Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin","volume":"51","author":"Aston-Mourney","year":"2008","journal-title":"Diabetologia"},{"key":"2022031210275318600_B13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2337\/db07-1285","article-title":"Cyclical and alternating infusions of glucose and intralipid in rats inhibit insulin gene expression and Pdx-1 binding in islets","volume":"57","author":"Hagman","year":"2008","journal-title":"Diabetes"},{"key":"2022031210275318600_B14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1152\/physiolgenomics.2001.6.1.3","article-title":"Further chromosomal mapping of a blood pressure QTL in Dahl rats on chromosome 2 using congenic strains","volume":"6","author":"Dutil","year":"2001","journal-title":"Physiol Genomics"},{"key":"2022031210275318600_B15","doi-asserted-by":"crossref","first-page":"E549","DOI":"10.1152\/ajpendo.00255.2006","article-title":"Lipid-induced beta-cell dysfunction in vivo in models of progressive beta-cell failure","volume":"292","author":"Goh","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031210275318600_B16","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2337\/diabetes.50.4.733","article-title":"Cerulenin mimics effects of leptin on metabolic rate, food intake, and body weight independent of the melanocortin system, but unlike leptin, cerulenin fails to block neuroendocrine effects of fasting","volume":"50","author":"Makimura","year":"2001","journal-title":"Diabetes"},{"key":"2022031210275318600_B17","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2337\/diabetes.49.3.424","article-title":"Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion","volume":"49","author":"Hohmeier","year":"2000","journal-title":"Diabetes"},{"key":"2022031210275318600_B18","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00007890-198705000-00024","article-title":"Reproducible high yield of rat islets by stationary in vitro digestion following pancreatic ductal or portal venous collagenase injection","volume":"43","author":"Gotoh","year":"1987","journal-title":"Transplantation"},{"key":"2022031210275318600_B19","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1210\/jcem.87.6.8578","article-title":"Comparison of insulin sensitivity, clearance, and secretion estimates using euglycemic and hyperglycemic clamps in children","volume":"87","author":"Uwaifo","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031210275318600_B20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1368-5031.2004.0108.x","article-title":"Long-term glycaemic control with pioglitazone in patients with type 2 diabetes","volume":"58","author":"Campbell","year":"2004","journal-title":"Int J Clin Pract"},{"key":"2022031210275318600_B21","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1021\/jm9804127","article-title":"N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents","volume":"41","author":"Henke","year":"1998","journal-title":"J Med Chem"},{"key":"2022031210275318600_B22","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1021\/jm801594x","article-title":"Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists","volume":"52","author":"Lin","year":"2009","journal-title":"J Med Chem"},{"key":"2022031210275318600_B23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.diabres.2006.08.015","article-title":"Beta-cell preservation with thiazolidinediones","volume":"76","author":"Campbell","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031210275318600_B24","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2337\/diabetes.49.5.735","article-title":"Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells","volume":"49","author":"Patan\u00e8","year":"2000","journal-title":"Diabetes"},{"key":"2022031210275318600_B25","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.2337\/diabetes.54.8.2447","article-title":"Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals","volume":"54","author":"Kim","year":"2005","journal-title":"Diabetes"},{"key":"2022031210275318600_B26","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1007\/s00125-007-0682-4","article-title":"Direct rosiglitazone-induced modifications in insulin secretion, action and clearance: a single-dose hyperglycaemic clamp study","volume":"50","author":"Farret","year":"2007","journal-title":"Diabetologia"},{"key":"2022031210275318600_B27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.metabol.2006.08.018","article-title":"Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone","volume":"56","author":"Osei","year":"2007","journal-title":"Metabolism"},{"key":"2022031210275318600_B28","doi-asserted-by":"crossref","first-page":"E175","DOI":"10.1152\/ajpendo.00453.2005","article-title":"Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues","volume":"291","author":"LeBrasseur","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031210275318600_B29","doi-asserted-by":"crossref","first-page":"e10405","DOI":"10.1371\/journal.pone.0010405","article-title":"Effects of long-term pioglitazone treatment on peripheral and central markers of aging","volume":"5","author":"Blalock","year":"2010","journal-title":"PLoS ONE"},{"key":"2022031210275318600_B30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1472-6823-9-10","article-title":"Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone","volume":"9","author":"Syversen","year":"2009","journal-title":"BMC Endocr Disord"},{"key":"2022031210275318600_B31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s13318-011-0039-8","article-title":"In vitro characterization of rosiglitazone metabolites and determination of the kinetic parameters employing rat liver microsomal fraction","volume":"36","author":"Calixto","year":"2011","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2022031210275318600_B32","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1007\/s00125-011-2311-5","article-title":"Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status","volume":"54","author":"Stephenne","year":"2011","journal-title":"Diabetologia"},{"key":"2022031210275318600_B33","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1172\/JCI40671","article-title":"Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1\/AMPK pathway via a decrease in hepatic energy state","volume":"120","author":"Foretz","year":"2010","journal-title":"J Clin Invest"},{"key":"2022031210275318600_B34","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1046\/j.1365-201X.2003.01164.x","article-title":"AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise","volume":"178","author":"Ruderman","year":"2003","journal-title":"Acta Physiol Scand"},{"key":"2022031210275318600_B35","doi-asserted-by":"crossref","first-page":"9780","DOI":"10.1074\/jbc.M109.065466","article-title":"Energy restriction as an antitumor target of thiazolidinediones","volume":"285","author":"Wei","year":"2010","journal-title":"J Biol Chem"},{"key":"2022031210275318600_B36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nbt.1606","article-title":"Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis","volume":"28","author":"Gohil","year":"2010","journal-title":"Nat Biotechnol"},{"key":"2022031210275318600_B37","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1152\/physiolgenomics.00069.2005","article-title":"Identification of potential caloric restriction mimetics by microarray profiling","volume":"23","author":"Dhahbi","year":"2005","journal-title":"Physiol Genomics"},{"key":"2022031210275318600_B38","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.tem.2008.07.006","article-title":"The islet beta-cell: fuel responsive and vulnerable","volume":"19","author":"Nolan","year":"2008","journal-title":"Trends Endocrinol Metab"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/62\/6\/2122\/573385\/2122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/62\/6\/2122\/573385\/2122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:31:36Z","timestamp":1667406696000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/62\/6\/2122\/15847\/Pioglitazone-Acutely-Reduces-Energy-Metabolism-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,20]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,5,20]]},"published-print":{"date-parts":[[2013,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db12-0428","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,20]]}}}